Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
PRECIGEN, INC. director Jeffrey B. Kindler received new equity awards as part of his board compensation. On March 10, 2026, he was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027.
He was also granted options on 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, he received 19,658 shares of common stock issued in lieu of an annual cash retainer of $69,000, bringing his directly held common stock to 130,261 shares.
PRECIGEN, INC. director Fred Hassan reported receiving new equity awards as compensation. He was granted 35,612 restricted stock units and an option for 41,073 shares of common stock at an exercise price of $3.51 per share, both dated March 10, 2026. He also received 17,948 shares of common stock, with a footnote stating these shares were issued in lieu of an annual cash retainer of $63,000. The restricted stock units vest in full on March 10, 2027, and the stock option expires on March 10, 2036. Following these awards, Hassan directly owns 1,171,400 shares of Precigen common stock.
PRECIGEN, INC. director Vinita D. Gupta reported equity awards received as compensation. On March 10, 2026, she was granted 35,612 restricted stock units representing the right to receive an equal number of common shares, vesting in full on March 10, 2027. She also received options to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, she acquired 17,948 shares of common stock, issued in lieu of an annual cash retainer of $63,000, bringing her direct common stock holdings to 594,188 shares after the transactions.
PRECIGEN, INC. director Frank Steven reported equity compensation grants consisting of common shares, restricted stock units, and stock options. He received 14,245 shares of common stock at $3.51 per share, issued in lieu of a $50,000 annual cash retainer, bringing his direct common stock holdings to 1,154,552 shares.
He was also granted 35,612 restricted stock units, each representing one share of common stock and vesting in full on March 10, 2027, plus options to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. These transactions are compensation-related awards rather than open‑market trading.
PRECIGEN, INC. director Cesar L. Alvarez received equity-based compensation rather than cash. He was issued 17,806 shares of common stock at $3.51 per share in lieu of an annual retainer of $62,500.
Alvarez was also granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027. In addition, he received an option to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. Following these awards, he directly owns 711,070 common shares. These are compensation grants, not open-market purchases.
PRECIGEN, INC. director Nancy H. Agee received equity-based compensation on March 10, 2026. She was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027. She also received an option to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, she was issued 16,096 shares of common stock in lieu of an annual cash retainer of $56,500. Following these awards, her directly held common stock position reported in this filing is 233,937 shares.
Precigen, Inc. reported a significant shareholder position from Patient Capital Management, LLC and its client fund. Patient Capital Management is deemed to beneficially own 36,006,800 shares of Precigen common stock, representing 10.18% of the class as of 12/31/2025.
Within this total, Patient Opportunity Trust, a Series of Advisor Managed Portfolios, is deemed to beneficially own 27,617,612 shares, or 7.8% of the common stock. The filer certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Precigen.
Point72 Asset Management and related entities have reported a significant passive stake in Precigen, Inc. common stock. As of the close of business on January 22, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly report beneficial ownership of 18,383,242 shares of Precigen common stock, representing 5.2% of the class.
The stake is held through Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. The reported amount includes 97,500 shares issuable upon exercise of call options. All three reporting persons share voting and dispositive power over the same 18,383,242 shares and certify that the securities were not acquired for the purpose of changing or influencing control of Precigen.
A director of Precigen, Inc. reported selling 235,467 shares of common stock on 12/12/2025. The shares were sold at a weighted average price of $3.6349, with individual trades executed at prices ranging from $3.5000 to $3.7100.
Following these sales, the director beneficially owns 110,603 shares of Precigen common stock in direct ownership. The filing notes that full details of the number of shares sold at each price within the stated range are available upon request.
Precigen, Inc. (PGEN) reported insider activity by director and 10% owner Randal J. Kirk on a Form 4. Through entity Kapital Joe, he sold 1,086,153 shares of common stock on 11/19/2025 at a weighted average price of $4.47, 942,832 shares on 11/20/2025 at a weighted average price of $4.08, and 937,308 shares on 11/21/2025 at $3.83.
The filing notes that the first two prices are weighted averages for multiple trades within reported price ranges, and Kirk undertakes to provide full trade details on request. After these sales, he continues to report large indirect beneficial ownership positions in Precigen through multiple entities, including 7,434,384 shares held by Kapital Joe and 82,164,767 shares held by R.J. Kirk Declaration of Trust, along with additional holdings through various family and investment vehicles.